Cargando…

Lenalidomide and Dexamethasone for a Patient of POEMS Syndrome Presenting with Massive Ascites

POEMS syndrome is a multisystem disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. POEMS syndrome is a rare cause of refractory ascites. We report the case of a patient with POEMS syndrome presenting with massive ascites who was treated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueda, Shuji, Yonemoto, Sayoko, Oka, Kazumasa, Fujii, Naohiko, Nakata, Keiichi, Matsunaga, Hitomi, Kataoka, Seiko, Iwama, Yuki, Narahara, Hiroyuki, Yasunaga, Yuichi, Inui, Yoshiaki, Kawata, Sumio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978405/ https://www.ncbi.nlm.nih.gov/pubmed/24782932 http://dx.doi.org/10.1155/2014/818946

Ejemplares similares

High Titer of Acquired Factor V Inhibitor Presenting with a Pseudo-deficiency of Multiple Coagulation Factors
por: Nakata, Keiichi, et al.
Publicado: (2017)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Improvement of sexual function in POEMS syndrome after combination therapy of Lenalidomide and dexamethasone
por: Yang, Hongbo, et al.
Publicado: (2016)

What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?
por: Zhao, Hao, et al.
Publicado: (2019)

Acute compartment syndrome as the initial manifestation of chronic-phase chronic myeloid leukemia: a case report and review of the literature
por: Nagase, Yoshikazu, et al.
Publicado: (2016)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone
por: Ikeda, Sho, et al.
Publicado: (2019)

Impact of lenalidomide exposure on blood cell collection for autotransplants in persons with POEMS syndrome
por: Cai, Hao, et al.
Publicado: (2016)

A rare cause of pericardial effusion and ascites: POEMS syndrome
por: Katipoglu, Bilal, et al.
Publicado: (2017)

POEMS syndrome: A rare cause of ascites and pelvic effusion
por: Ma, Jing, et al.
Publicado: (2022)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Schnitzler Syndrome after COVID-19 Vaccination
por: Asako, Mizuki, et al.
Publicado: (2022)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Daratumumab–bortezomib–dexamethasone use in relapsed POEMS syndrome
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

Skin Responses in Newly Diagnosed Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome After Therapy With Low-Dose Lenalidomide Plus Dexamethasone
por: Gao, Yajuan, et al.
Publicado: (2021)

A case of scleromyxedema responding to lenalidomide and dexamethasone
por: Rambhia, Sweta, et al.
Publicado: (2017)

Coronary spastic angina in a multiple myeloma patient treated with bortezomib, lenalidomide, and dexamethasone
por: Yasui, Taku, et al.
Publicado: (2020)

Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial
por: Suichi, Tomoki, et al.
Publicado: (2020)

Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis
por: Narla, Anupama, et al.
Publicado: (2011)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
por: Minarik, Jiri, et al.
Publicado: (2021)

First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS)
por: Sevindik, Omur Gokmen, et al.
Publicado: (2022)

IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification
por: Nakahara, Wataru, et al.
Publicado: (2023)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?
por: Hsu, Andy, et al.
Publicado: (2012)

Ascites as a presenting sign of multicentric mixed-type Castleman disease variant of POEMS syndrome
por: Kasinathan, Ganesh, et al.
Publicado: (2021)

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
por: Mateos, María-Victoria, et al.
Publicado: (2017)

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan
por: Suzuki, Kenshi, et al.
Publicado: (2017)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Siegel, D S, et al.
Publicado: (2014)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Siegel, D S, et al.
Publicado: (2014)

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
por: Mele, Giuseppe, et al.
Publicado: (2018)

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
por: Casneuf, Tineke, et al.
Publicado: (2020)

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
por: Hitz, F., et al.
Publicado: (2019)

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years
por: Yokoyama, Akihiro, et al.
Publicado: (2022)

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL
por: Dimopoulos, MA, et al.
Publicado: (2022)

Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
por: Onda, Yoshiyuki, et al.
Publicado: (2022)

Multilineage Lymphoblastic Lymphoma as an Initial Presentation of Mixed Phenotype Acute Leukemia
por: Ikeda, Mako, et al.
Publicado: (2023)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_dck4gipmogc4ir10uvj41754f6